|
WO2021051082A1
|
|
Methods of improving spinal fusion with abaloparatide
|
|
WO2020174443A1
|
|
Transdermal system for the delivery of abaloparatide and method of use
|
|
WO2020144653A1
|
|
Methods for detecting neutralizing antibodies to parathyroid hormone (pth) and parathyroid hormone-related peptide (pthrp) analog
|
|
US2020057041A1
|
|
Abaloparatide formulations and methods of testing, storing, modifying, and using same
|
|
EP3474841A1
|
|
Ar+ breast cancer treatment methods
|
|
CA3020333A1
|
|
Formulations of abaloparatide, transdermal patches thereof, and uses thereof
|
|
EP3359241A1
|
|
Formulations of pthrp analogues, transdermal patches thereof, and uses thereof
|
|
WO2016176664A1
|
|
Methods for treating cancer
|
|
WO2016141250A1
|
|
USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK
|
|
EP3332799A1
|
|
Method of drug delivery for pth, pthrp and related peptides
|
|
BR112013007685A2
|
|
applications related to selective amphrogen receptor modulators
|
|
HUE030072T2
|
|
Therapeutic regimens
|
|
MX2012008995A
|
|
Selective androgen receptor modulators.
|
|
WO2010030787A1
|
|
Estrogen receptor ligands
|
|
WO2009137104A1
|
|
Combination therapy for breastcancer comprising an antiestrogenic agent
|
|
CA2716320A1
|
|
Selective androgen receptor modulators
|
|
US2009227498A1
|
|
Method of treating osteoporosis comprising administration of PTHrP analog
|
|
KR20090083350A
|
|
Method of drug delivery for bone anabolic protein
|
|
EP2037905A2
|
|
Treatment of vasomotor symptoms with selective estrogen receptor modulators
|
